GlassScriptPhysician profile
Ibrahim M Al-Sanouri
NPI 1356452833
$7,469.82
in general payments reported to CMS, 2019-2025
36 companies · $4,174 in 2025
The $4,174 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,581 · 2020: $102 · 2021: $201 · 2022: $358 · 2023: $354 · 2024: $699 · 2025: $4,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,733 · Food and Beverage: $1,539 · Travel and Lodging: $954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,733.21 |
| Food and Beverage | $1,539.46 |
| Travel and Lodging | $954.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,471.25 | 2025 | |
| Veran Medical Technologies, INC. | $1,315.90 | 2019 | |
| Glaxosmithkline, LLC. | $486.17 | 2019-2025 | Nucala, Trelegy Ellipta |
| Amgen INC. | $414.58 | 2022-2025 | Tezspire, Tavneos |
| Regeneron Healthcare Solutions, INC. | $340.06 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $226.36 | 2019-2025 | Fasenra, Airsupra |
| Genzyme Corporation | $197.36 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.09 | 2019-2024 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Insmed, INC. | $92.43 | 2024-2025 | Arikayce, Brinsupri |
| Inspire Medical Systems, INC. | $75.88 | 2024 | Inspire |
| Mylan Specialty L.P. | $73.84 | 2019-2024 | Yupelri |
| Baxter Healthcare | $48.23 | 2023 | Hillrom - Life 2000 Ventilation System |
| Harmony Biosciences LLC | $46.18 | 2020-2024 | |
| Pulmonx Corporation | $40.03 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $39.47 | 2019-2024 | Prolastin-C Liquid |
| Circassia INC. | $34.40 | 2019-2020 | |
| Genentech USA, INC. | $31.14 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $29.78 | 2019-2024 | Opsumit |
| Electromed, INC. | $24.97 | 2022 | |
| Pfizer INC. | $23.97 | 2025 | |
| Alexion Pharmaceuticals, INC. | $23.28 | 2022 | |
| Resmed Corp | $22.11 | 2023 | |
| Novartis Pharmaceuticals Corporation | $22.03 | 2022 | |
| United Therapeutics Corporation | $20.27 | 2024 | Tyvaso |
| 3b Medical, INC. | $17.62 | 2025 | Luna |
| Merck Sharp & Dohme LLC | $17.59 | 2019 | |
| Lilly USA, LLC | $17.11 | 2025 | Zepbound |
| Boston Scientific Corporation | $15.75 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.23 | 2024 | Glassia |
| Allergan, INC. | $14.36 | 2019 | |
| Verona Pharma, INC. | $14.02 | 2025 | Ohtuvayre |
| Shire North American Group INC | $13.07 | 2019 | |
| Mallinckrodt Enterprises LLC | $12.42 | 2019 | |
| Bard Access Systems, INC. | $12.39 | 2019 | |
| Jazz Pharmaceuticals INC. | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahim Al-Sanouri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.